five-year os data for dabrafenib/trametinib combo in melanoma
Published 7 years ago • 818 plays • Length 1:03Download video MP4
Download video MP3
Similar videos
-
0:56
5-year follow-up: dabrafenib plus trametinib reduces relapse risk in melanoma
-
1:24
adverse events with dabrafenib/trametinib combination in melanoma
-
0:54
activity of dabrafenib/trametinib combo in patients with melanoma brain metastases
-
0:53
dabrafenib plus trametinib demonstrates benefit in braf-mutant melanoma
-
1:24
adverse events with dabrafenib/trametinib combination in melanoma
-
2:19
dr. robert on 5-year analysis of dabrafenib/trametinib in braf v600-mutant melanoma
-
3:05
dabrafenib and trametinib: a promising combination for the treatment of melanoma
-
0:48
dr. michael rotkowitz on the dabrafenib plus trametinib combination for melanoma
-
2:33
dr. sullivan discusses role of dabrafenib plus trametinib in melanoma
-
0:44
dr. michael rotkowitz on dabrafenib and trametinib combination side effects
-
1:04
dr. wilson on long-term data with dabrafenib plus trametinib in melanoma
-
3:18
dabrafenib plus trametinib for the treatment of mnsclc
-
0:59
the success of the dabrafenib and trametinib combination in braf-mutated melanoma
-
2:12
phase iii combi-d study of dabrafenib and trametinib in patients with melanoma
-
1:31
dr. daud on dabrafenib/trametinib vs immunotherapy in melanoma
-
1:52
dr. long on dabrafenib/trametinib in braf v600e-mutant melanoma
-
4:08
updates from combi-ad: dabrafenib and trametinib for melanoma
-
1:46
dr. weber on dabrafenib/trametinib approval for melanoma
-
6:28
dabrafenib and trametinib in braf-mutated nsclc